Management of Renal Impairment

Introduction to Renal Impairment Management

• The Kidney International guideline recommends providing adequate hydration with oral or intravenous fluids for dehydration, and considering renal replacement therapy for severe cases with significant symptoms 1
• The Arthritis care & research guideline notes that low-dose aspirin (≤325 mg daily) has only modest effects on urea levels and should not be discontinued if used for cardiovascular prophylaxis 2

Dietary Recommendations

• The Arthritis care & research guideline suggests avoiding high purine foods if hyperuricemia is also present 2
• High fructose intake from sugar-sweetened beverages is associated with an increased risk of hyperuricemia, as reported by the Autoimmunity Reviews 3
• Dietary factors, including high intake of purine-rich foods (meat, seafood) and alcohol consumption, especially beer and spirits, can increase the risk of gout development, with a relative risk of 1.51 for seafood and 1.49 per serving/day for beer, as acknowledged by the American College of Rheumatology and the European League Against Rheumatism 4
• Lifestyle changes, including reducing intake of purine-rich foods, weight loss in overweight individuals, limiting alcohol consumption, especially beer and spirits, increasing fluid intake, avoiding sugar-sweetened drinks, limiting excessive intake of meat and seafood, encouraging low-fat dairy products, and regular exercise, can help manage gout risk, with a relative risk reduction associated with these lifestyle changes, as recommended by the American Heart Association and the European League Against Rheumatism 4, 5

Treatment of Renal Impairment

• The Kidney International guideline recommends considering dialysis, especially if symptomatic or refractory to other measures, for severe elevation of urea levels 1
• Medications such as thiazide and loop diuretics, low-dose aspirin, and calcineurin inhibitors can contribute to hyperuricemia, with a modest effect observed with low-dose aspirin, as acknowledged by the American College of Rheumatology and the Arthritis Care & Research 2
• The KDIGO 2024 guidelines and the American College of Rheumatology do not recommend pharmacologic urate-lowering therapy for asymptomatic hyperuricemia 6, 2, 7
• Uric acid-lowering therapy is recommended for people with symptomatic hyperuricemia, with xanthine oxidase inhibitors (allopurinol, febuxostat) preferred over uricosuric agents, as recommended by the KDIGO 2024 guidelines 6
• Low-dose colchicine or intra-articular/oral glucocorticoids are preferable to NSAIDs, especially in patients with CKD, as recommended by the KDIGO 2024 guidelines 6
• Allopurinol should be started at a low dose (100 mg/day) and adjusted based on renal function, according to the European League Against Rheumatism 5
• Regular monitoring of uric acid levels (every 3-6 months) is recommended, as well as monitoring kidney function and hydration status in patients with gout, as recommended by the American College of Rheumatology 2
• Urinary alkalinization with potassium citrate is the cornerstone of treatment to increase urine pH to approximately 6.0, with potassium citrate preferred over sodium citrate due to the potential for increased urine calcium excretion with sodium citrate, and the initial dosage is 30-60 mEq/day based on severity of the condition, as recommended by the American College of Rheumatology 8, 9
• Consider discontinuation of non-essential medications that elevate uric acid (thiazides, loop diuretics) if possible, as suggested by the American College of Rheumatology 2

Biochemical Considerations

• Urea and uric acid are distinct biochemical compounds with different molecular structures, metabolic pathways, and physiological roles in the human body, with urea being the end product of protein metabolism and uric acid being the end product of purine nucleic acid catabolism, according to the American College of Clinical Oncology 10
• Uric acid solubility is highly dependent on pH, with a solubility of approximately 15 mg/dL at pH 5.0 and approximately 200 mg/dL at pH 7.0, as reported by the Journal of Clinical Oncology 10, 8

Special Considerations

• Higher risk of medication side effects and drug interactions in elderly patients requires careful consideration, as noted by the American Geriatrics Society 2
• Renal function often reduced in elderly patients, requiring dose adjustments, according to the American College of Rheumatology 2
• Comorbidities may complicate management, and polypharmacy concerns require careful medication review, as recommended by the American College of Physicians 7
• The European League Against Rheumatism recommends assessment for renal uric acid excretion in patients with a family history of young-onset gout, onset of gout under age 25, or history of renal calculi 11
• A 24-hour urine collection can be used to assess uric acid/creatinine ratio and categorize patients as overexcreters, normoexcreters, or underexcreters, as suggested by the Annals of the Rheumatic Diseases 11
• Monitoring includes 24-hour urine collection within 6 months of initiating treatment and annual 24-hour urine specimens to assess adherence and metabolic response, as well as monitoring serum electrolytes, creatinine, and complete blood counts every four months, as recommended by the American College of Rheumatology 9
• Genetic polymorphisms affecting renal transporters of urate can contribute to hyperuricemia, according to the European League Against Rheumatism 3